Doxorubicin Adverse Reaction
4
0
0
1
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Treatment Research
6 treatments under study, led by Control Groupdh001 Placebo
Related Conditions
Often studied with 11 related conditions
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
0.0%
0 terminated out of 4 trials
100.0%
+13.4% vs benchmark
0%
0 trials in Phase 3/4
0%
0 of 1 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 1 completed trials
Clinical Trials (4)
The Impact of Using Nicorandil for the Prevention of Doxorubicin-Induced Cardiotoxicity
Acupuncture as add-on to G-CSF for Febrile Neutropenia-related Hospitalization in Doxorubicin-treated Patients With Sarcoma
A Multicenter Clinical Trial on DH001 Tablets in the Prevention of Doxorubicin-induced Cardiotoxicity in Cancer Patients
The Role of suPAR Biomarker in Blood Samples of Breast Cancer Patients During and Post Doxorubicin Chemotherapy: Causative vs. Predictor
Research Network
Common Treatments
- Control Groupdh001 Placebo1
- Doxorubicin1
- Trial Group Dh001 Highdose Group1
- Trial Group Dh001 Lowdose Group1
- Acupuncture1
Active Sponsors
- Universiti Sains Malaysia1
- Monyan Pharmaceutical (Shanghai) Co., Ltd.1
- Rush University Medical Center1
- Shaare Zedek Medical Center1
Top Investigators
Universiti Sains Malaysia
The First Affiliated Hospital of Dalian Medical University
Universiti Sains Malaysia
Peking University Third Hospital
Henan Cancer Hospital
Related Conditions
- Doxorubicin Induced Cardiomyopathy2
- Breast Cancer1
- Hospitalizationassociated Infection1
- Sarcoma1
- Cancer1